Fundamentals of Clinical Trials: Week 2
We first provide a brief background on the multi-target cardiovascular effects of TCM-derived metabolites (Figure 1), then discuss evidence for their benefits in specific disease contexts (atherosclerosis, hypertension, myocardial infarction, heart failure), integrate findings from clinical studies, and finally consider the challenges and future directions for translating these therapies into mainstream cardiovascular care
White M, Damania A, Alshenaifi J, Sahasrabhojane P, Peacock O, Losh J, Wong MC, Berkova Z, Nguyen ST, Chang GJ, Wargo JA, Ajami NJ, Kopetz S , You Y
DBI (diazepam binding inhibitor also known as GABA receptor modulator or acyl-coenzyme A (acyl-CoA) binding protein (ACBP) acts as intracellular acyl-CoA transporter, forming a pool of ACBP-acyl-CoA complex which is an important intermediate in lipid metabolism (Alquier et al